IRLAB publishes interim report for the period January – June 2025
Gothenburg, Sweden, August 27, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January – June 2025, has been published.
Read More >IRLAB carries out SEK 136m rights issue
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation by Kristina Torfgård, CEO, at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >